The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

As weight loss medications, including Ozempic and WeGovy, have gained popularity across the U.S., they are not without side effects, some serious. According to a May 2024 CNN report, as many as 1 in 8 ...

Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

--The company currently guides for 16%-24% sales growth at constant exchange rates and for 19%-27% operating profit growth. "With the continued weak trends in the U.S. continuing into 2Q, we now ...

Another was a looming late-stage clinical trial of a closely watched pipeline drug that's loaded with potential. For a ...

As weight-loss injectables like Ozempic skyrocket in popularity, a new offshoot trend is starting to take hold: microdosing. But experts have concerns.

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...